Gainers & Losers Of The Day: DXCM, CYAD, SKLN, SSH...

(RTTNews) - The following are the biotech stocks that made their way onto the Day's Gainers & Losers' list of January 13, 2017.

GAINERS

1. DexCom Inc. (DXCM)

Gained 25.91% to close Friday's (Jan.13) trading at $85.13.

News: The Centers for Medicare & Medicaid Services (CMS) has classified the company's therapeutic Continuous Glucose Monitors as "Durable Medical Equipment" under Medicare Part B.

The new classification means that Continuous Glucose Monitors are now covered under Medicare.

Continuous glucose monitoring (CGM) is a small wearable device that tracks one's glucose throughout the day and night for the purpose of adjusting their diet and insulin in the treatment of their diabetes.

2. Celyad SA (CYAD)

Gained 13.99% to close Friday's trading at $21.66.

News: No news

Near-term catalyst:

The company's most advanced product candidate is CAR-T NKR-2. A Belgian phase Ib study to assess the safety and clinical activity of multiple administrations of autologous CAR-T NKR-2 cells in seven refractory cancers, including five solid and two hematological tumors, is ongoing. Results from this study are expected this year.

3. Achaogen Inc. (AKAO)

Gained 13.60% to close Friday's trading at $17.96.

News: No news

Near-term catalyst: Achaogen plans to submit a New Drug Application for Plazomicin to treat serious bacterial infections due to multidrug-resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae, in the second half of 2017.

4. Aviragen Therapeutics Inc. (AVIR)

Gained 11.44% to close Friday's trading at $1.40.

News: No news

Near-term catalysts:

-- Data readout from a Phase 2a challenge study of BTA585 in healthy volunteers challenged intranasally with respiratory syncytial virus (RSV) is expected in next several weeks. -- Data readout from a Phase 2b trial of Vapendavir, dubbed SPIRITUS, in human rhinovirus (HRV) infected patients with moderate-to-severe asthma is expected in next several weeks. -- A response to the clinical hold imposed by the FDA on the company's investigational drug BTA585 for the treatment and prevention of respiratory syncytial virus (RSV) infections is planned for this quarter. The FDA placed the clinical hold on BTA585 last May.

LOSERS

1. Cellect Biotechnology Ltd. (APOP)

Lost 28.81% to close Friday's trading at $4.35.

News: No news

Pullback after Thursday's gain of 84.04%.

2. Skyline Medical Inc. (SKLN)

Lost 15.25% to close Friday's trading at $2.39.

News: Public offering of common stock and warrants.

The company has priced the public offering of 1.75 million Units at an offering price of $2.25 per Unit. Gross proceeds to the company from the offering will be approximately $3.94 million. The offering is expected to close on January 18, 2017.

3. Transgenomic Inc. (TBIO)

Lost 12.50% to close Friday's trading at $0.98.

News: No news

Pullback after Thursday's gain of more than 295%.

4. Zogenix Inc. (ZGNX)

Lost 10% to close Friday's trading at $10.35.

News: No news

Near-term catalyst: Top-line results from two phase III safety and efficacy clinical trials of ZX008, dubbed Studies 1501 and 1502, for Dravet syndrome are anticipated in Q2 2017.

5. Sunshine Heart Inc. (SSH)

Lost 7.46% to close Friday's trading at $8.19.

News: 1-for-30 reverse split of common stock came into effect at 5:00 pm Eastern time Friday.

Following the reverse split, the number of authorized shares of the company's common stock will remain at 100 million, while the number of outstanding shares will be reduced from approximately 25.3 million to 0.8 million.